It is one listing and one ticker: West Pharmaceutical Services' common stock trades on the New York Stock Exchange as WST, so a broker that offers US shares can fill the order. What the share buys into is less obvious, because West sells the rubber stoppers, seals and syringe parts that sit inside other companies' injectable drugs, and in 2025 its ten largest customers accounted for 47.6% of net sales. This guide covers the business, the order itself, and the drivers its filings point to, from biologic and GLP-1 demand to a 2026 cyberattack and a pending securities lawsuit.
What Does West Pharmaceutical Do?
Its annual report calls the company "a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products." The customers are drugmakers: biologic, generic and pharmaceutical companies, plus diagnostic and medical device firms.
The core product is the elastomer closure. A vial of injectable medicine is closed with a rubber stopper and an aluminum seal, and the 10-K says these parts are designed to help keep the drug compatible and stable. West makes those stoppers and seals, along with plungers and other components for prefilled syringes and cartridges. Films, coatings, washing, inspection and sterilization are added so that components arrive ready for filling. Its three main raw materials, according to the 10-K, are elastomers, aluminum and plastic.
Beyond components, West sells vials, syringes and cartridges that the 10-K presents as an answer to drugs that do not sit well in glass, able to handle cold storage with less risk of breakage. They include Crystal Zenith vials, syringes and cartridges; Crystal Zenith is a trademark of West's Japanese affiliate Daikyo Seiko. The company also sells self-injection devices for at-home use, administration systems for mixing and transferring drugs, and analytical lab services that test how a drug behaves with its package. In January 2026 it launched the Synchrony prefillable syringe system.
These activities are reported in two segments. Proprietary Products covers West's own components, containment and devices. The second segment designs and assembles devices that customers own, such as surgical, diagnostic and drug delivery devices; it was called Contract-Manufactured Products until early 2026, when West renamed it West Vantage without changing what it contains.
Daikyo is more than a supplier. West owns 49% of the company, and the 10-K says key value-added products and processes, including Crystal Zenith and FluroTec coatings, are licensed from it. West headquarters are in Exton, Pennsylvania, and at the end of 2025 it employed about 10,800 people, around 42% of them in Europe. The 10-K names Datwyler and Aptar as competitors for components, and SMC Ltd. and Phillips Medisize in contract manufacturing.
How West Pharmaceutical Makes Money
In 2025, net sales grew 6.3%, or 4.3% excluding currency effects. Proprietary Products supplied about 81% of the total. The company sorts revenue by product category, and the split shows where the value sits:
| Product category | Share of 2025 net sales | Share of 2024 net sales |
|---|---|---|
| High-value product components | 47% | 45% |
| High-value product delivery devices | 13% | 14% |
| Standard packaging | 21% | 22% |
| Contract-manufactured products (West Vantage) | 19% | 19% |
The filings report these categories without listing every product in each. What they do say is that the third-quarter 2026 rise in high-value delivery devices came mainly from Crystal Zenith and administration systems.
By market, biologics customers made up 40% of 2025 net sales, generics 17% and other pharmaceutical customers 24%, with contract manufacturing providing the remaining 19%.
The gap in profitability between the two segments is wide. Proprietary Products earned a gross margin of 40.5% in 2025, against 16.5% at the contract-manufacturing segment. The 10-K credits the Proprietary increase to stronger demand, "primarily of high value components," better plant absorption and price increases, and it names Westar, NovaChoice and Envision as the products behind the sales gain. In contract manufacturing, self-injection devices for obesity and diabetes grew while diagnostic devices declined.
Concentration is the other structural fact. The ten largest customers accounted for 47.6% of 2025 net sales, and one of them alone for 15.8%, with sales in both segments. The 10-K does not name that customer. Sales outside the United States made up 56.7% of the total, so most revenue is earned in other currencies and translated into dollars.
WST Stock at a Glance
| Feature | WST |
|---|---|
| Exchange | New York Stock Exchange |
| Ticker | WST |
| Security | Common stock, the only class registered under Section 12(b) |
| Sector | Packaging, containment and delivery systems for injectable drugs |
| Segments | Proprietary Products; West Vantage (formerly Contract-Manufactured Products) |
| Index membership | S&P 500 |
| Headquarters | Exton, Pennsylvania |
| Incorporated | Pennsylvania |
| Fiscal year | Calendar year, ending 31 December |
| Payouts | Quarterly cash dividend, plus share repurchases in 2025 and 2026 |
| Chief executive | Michel Lagarde, since 31 August 2026 |
| SEC identifier | CIK 105770 |
Quotes, market value and yield shift all day, so this table leaves them out; the West Pharmaceutical stock page on Bitbase shows them live.
How to Buy West Pharmaceutical Stock
West is a Pennsylvania company and its shares list directly in New York, so there is no depositary receipt in between. A purchase runs in six steps:
1. Find a broker that reaches the NYSE. Outside the United States, that may be a local firm with a US market link or an international broker. Check which entity holds the account and who regulates it.
2. Complete the account checks. Brokers verify identity, and non-US residents are normally asked for IRS Form W-8BEN, which the IRS says should be submitted when the withholding agent or payer requests it.
3. Move money in. If your account is funded in another currency, the conversion rate is part of the cost, not just the commission.
4. Search for WST and read the result. The listing should say West Pharmaceutical Services, Inc. common stock on the New York Stock Exchange.
5. Choose how the order executes. FINRA describes a market order as the one most likely to be filled, without control over price, while a limit order fills only at your stated price or better.
6. Decide on whole or partial shares. Some brokers sell fractions of a share, which lets you invest a fixed amount; FINRA notes that availability varies by firm and that fractional owners may not get voting rights.
Withholding tax. According to the IRS, most US-source income paid to a foreign person is taxed at 30% unless a lower treaty rate or exemption applies, which is why brokers collect the W-8BEN. Your home country may tax the same dividend again.
Owning it indirectly. WST is part of the S&P 500; on 10 November 2026, State Street's daily holdings file for its SPY fund listed West Pharmaceutical Services. Any fund tracking that index holds a small slice of WST alongside hundreds of other companies.
What Moves WST Stock
Biologic and GLP-1 demand. High-value components have led recent growth, and their volume follows the injectable drugs they go into. In the third quarter of 2026, organic sales of these components rose 20.3%, which the 10-Q attributes to "continued strong customer demand for both Biologics and GLP-1 products" as well as price increases. They made up 53% of net sales in that quarter, against 47% across 2025.
Product mix. Proprietary Products, home of the high-value lines, earned a far wider gross margin in 2025 than contract manufacturing, so the balance between them shapes earnings. Group organic net sales rose 11.9% in the third quarter of 2026, while West Vantage fell 6.6% on an organic basis after a planned expiry of a continuous glucose monitoring customer contract at one of its facilities.
Portfolio changes. On 1 July 2026 West completed the sale to AbbVie of the manufacturing and supply rights for one version of its SmartDose on-body delivery system. Organic growth figures exclude that product.
The Daikyo agreements. The 10-K warned that West's licences for Daikyo technology ran under agreements expiring in 2027 and that "if the agreements are terminated early or not renewed, our business could be adversely impacted." In July 2026 the two companies signed replacement crosslicense and distributorship agreements, each with a 10-year term, that can still end early in some cases, including a change in control of either party.
Leadership and one-off events. Chief executive Eric Green told the board in March 2026 that he intended to retire. Michel Lagarde, previously chief operating officer of Thermo Fisher Scientific, took over on 31 August 2026. Between those dates, on 7 May, West disclosed a material cyberattack in which data was stolen and systems were encrypted. By 20 May it reported that all sites were operating again, though its investigation was continuing. In October 2026 the company raised its full-year 2026 guidance and lifted its quarterly dividend by 18%.
Currency. With most sales earned abroad, exchange rates move reported results: 2025 growth was 6.3% as reported and 4.3% at constant currency.
Oral Doses, Single Suppliers and Other Risks West Names
The risk factors in the 10-K that bear most directly on the share include these:
Dependence on injection. "Our sales and profitability are largely dependent on the sale of drug products delivered by injection." The company names the case of customers moving to "oral GLP-1s" and of drugs reformulated for "less frequent dosing" as threats to its sales.
Pricing and customer power. West says it faces "continued pricing pressure from our customers and competitors," and that consolidation among drugmakers and group purchasing organizations adds to it. With one customer at 15.8% of sales, losing or repricing a large account would show quickly.
Supply and plants. Many components and raw materials come "only from a single supplier," and regulatory requirements make quick substitution hard. Production of "certain product lines is concentrated in one or only a few of our plants," so a disruption at one site can affect output.
Cybersecurity. The 10-K said West's systems "have and may in the future become the target of cyberattacks." The May 2026 incident took systems offline worldwide; the 10-Q for the third quarter records professional fees related to it.
Litigation. A securities class action filed on 5 May 2025 in the Eastern District of Pennsylvania, on behalf of investors who bought shares between 16 February 2023 and 12 February 2025, alleges that public statements about the business broke securities law. West has moved to dismiss, calls the claims "without merit," and says it cannot yet estimate any loss.
Trade and currency. Tariffs, foreign exchange and political conditions abroad can all reduce results, and the company's hedges may not fully offset them.
Two risks belong to the stock itself. One company is concentrated exposure, however steady its customers look, and dividends are not fixed: the board declares them "at the discretion of our Board of Directors" after weighing earnings, cash needs and other factors.
How to Research WST Yourself
West files with the SEC under CIK 105770. The 10-K describes the segments and risks, the 10-Qs cover the first three quarters, and 8-Ks carry events such as the earnings releases, which in 2026 came on 12 February, 23 April, 23 July and 29 October. The same documents are posted under the Investors section of westpharma.com.
In the filings, the revenue note splits net sales by market group and product category, which is where the high-value share appears; the segment note sets Proprietary Products against West Vantage, the 2026 name for what earlier reports called Contract-Manufactured Products; and the legal proceedings section tracks the class action.
When comparing growth, check whether a figure is reported, organic or at constant currency. For another listed maker of syringes and prefillable syringes for drugmakers, our Becton Dickinson stock guide covers that company's segments and filings. Live prices are on the WST page linked above, and the full directory of US stock pages on Bitbase lists other companies.
West Pharmaceutical Stock FAQ
Can I buy West Pharmaceutical stock with crypto?
Not directly. WST shares are bought through a brokerage account funded in dollars or another currency the broker accepts, so crypto would first have to be sold for cash and transferred, and that sale may be taxable where you live. A share also carries dividend and voting rights in a registered company, which is part of how a share differs from a crypto asset.
Does West Pharmaceutical pay a dividend?
Yes. West pays a quarterly cash dividend, and in October 2026 the board raised it by 18%. The board decides each payment at its discretion, so check the latest 8-K or earnings release for the current amount and dates.
Is WST in the S&P 500?
Yes. State Street's SPY holdings file dated 10 November 2026 includes West Pharmaceutical Services. The 10-K also compares WST's five-year shareholder return with the S&P 500 and the S&P 500 Health Care Index.
What is West Vantage?
It is the new name, from the first quarter of 2026, for the segment formerly called Contract-Manufactured Products. It designs, molds and assembles devices that belong to customers, and it provided 19% of 2025 net sales. West says the change did not alter what the segment contains or its previously reported figures.
What is West's relationship with Daikyo?
West owns 49% of Daikyo Seiko, its affiliate in Japan, and licenses technologies such as Crystal Zenith and FluroTec from it. Under agreements effective July 2026, each with a 10-year term, West is Daikyo's exclusive distributor outside Japan, with limited exceptions.
Conclusion
West's share price ultimately rests on how much of the world's injectable medicine flows through its stoppers, plungers and Crystal Zenith containers, and on how much of that is the high-value kind. The filings show both the strength and the narrowness of that position: margins built on biologics and GLP-1 demand, a customer list where one buyer accounts for nearly a sixth of sales, and technology tied to a Japanese partner. Read the latest 10-K and quarterly release, watch the product mix and the class action, and size any holding as one specialized supplier inside a wider portfolio.
Related reading
Other Bitbase articles on this topic:
- How to Buy Humana Stock (HUM): Medicare Advantage and CenterWell
- How to Buy Illumina Stock (ILMN): Reagents, China and GRAIL
- How to Buy Intuitive Surgical Stock (ISRG): da Vinci, No Dividend
Disclaimer: This article is educational content from Bitbase Academy, provided for information only. It explains what a company or fund does and how the instruments referenced here differ from one another; it does not constitute investment, trading, tax, or financial advice, and it is neither a recommendation nor an endorsement of any security, token, or trading strategy. A tokenized stock is issued by a third party and is designed to give economic exposure to an underlying asset: it is not a share, it carries no shareholder rights, and it depends on the issuer's structure, eligibility rules, and redemption terms, which the issuer can change. Perpetual futures are leveraged derivatives that hold no underlying asset and can be liquidated, and trading hours, product availability, and eligibility differ by instrument and by jurisdiction and can change at any time. Written as of November 2026; verify everything yourself through company filings, the issuer's own documentation, and the product pages of the venue you trade on.
References
[1] West Pharmaceutical Services Form 10-K for 2025 (SEC EDGAR) www.sec.gov
[2] West Pharmaceutical Services 2025 Form 10-K, XBRL cover page (SEC EDGAR) www.sec.gov
[3] West Pharmaceutical Services Form 10-Q for the third quarter of 2026 (SEC EDGAR) www.sec.gov
[4] West Pharmaceutical Services third-quarter 2026 earnings release, filed with Form 8-K (SEC EDGAR) www.sec.gov
[5] West Pharmaceutical Services Form 8-K of 11 May 2026: cybersecurity incident (SEC EDGAR) www.sec.gov
[6] West Pharmaceutical Services Form 8-K/A of 20 May 2026: cybersecurity update (SEC EDGAR) www.sec.gov
[7] West Pharmaceutical Services Form 8-K of 1 June 2026: new chief executive (SEC EDGAR) www.sec.gov
[8] West Pharmaceutical Services Form 8-K of 14 July 2026: Daikyo agreements (SEC EDGAR) www.sec.gov
[9] State Street SPDR S&P 500 ETF Trust (SPY): fund page and daily holdings www.ssga.com
[10] FINRA: Order Types www.finra.org
[11] FINRA: Investing in Fractional Shares www.finra.org
[12] IRS: NRA Withholding www.irs.gov
[13] IRS: About Form W-8 BEN www.irs.gov






